NuCana

$2.93 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NuCana

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. Its pipeline includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. Acelarin is designed to generate and maintain higher concentrations of the anti-cancer metabolite inside the tumor. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). NUC-3373 is being developed for patients with advanced solid tumors. It is developing NUC-3373 as a therapy for colorectal cancer and other solid tumors. NUC-7738 is a ProTide of 3’-deoxyadenosine and is able to enter cells independently of nucleoside transporters. It is developing NUC-7738 for patients with either solid or hematological malignancies.

Stock Analysis

last close $2.93
1-mo return -33.7%
3-mo return -50.8%
avg daily vol. 211.74T
52-week high 7.83
52-week low 2.8
market cap. $150M
forward pe -
annual div. -
roe -37.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 50.9%
baraka

Subscribe now for daily local and international financial news

Subscribe